在实际应用中，介入放射学导航系统被广泛用于肿瘤消融、穿刺活检、血管介入、神经介入、经皮引流以及复杂解剖区域的 微创治疗。例如在肝脏肿瘤消融中，医生可在三维导航界面上规划最佳进针路径，避开血管与重要结构，同时系统实时校正 针尖位置，提高穿刺准确率，减少反复进针。在血管类介入操作中，导航系统能够显示导丝在弯曲血管中的方位，使复杂的 血管入路更加简化，减少对造影剂和透视的依赖，从而降低辐射暴露。在硬膜外腔穿刺、肺小结节活检或深部骨盆病灶穿刺 中，导航系统同样能够有效补偿呼吸运动、体位变化等因素带来的误差。 发展前景 总体而言，介入放射学导航系统通过高精度影像、空间追踪和智能算法的结合，为微创治疗提供精准路径和实时定位，使介 入手术更加安全、高效和可控。它不仅优化了临床流程，也推动了介入医学向精细化、智能化方向发展，成为现代微创治疗 体系中不可或缺的核心技术。 随着人工智能、机器人技术和多模态融合影像的发展，介入放射学导航系统正向更高精度、更智能和更自动化的方向演进。 AI 算法可用于预测最佳穿刺轨迹、识别关键结构并实时调整导航数据，提高系统对动态组织的适应性。机器人臂结合导航系 统可执行稳定而精确的针路控制，进一步 ...

System-level digital twins for SDVs using existing technologies can be complex and time consuming to create and validate. To solve this bottleneck, PAVE360 Automotive delivers a fully integrated, system-level digital twin that can be deployed on day one – reducing the time, effort and cost required to build such environments from scratch. PAVE360 Automotive using Arm Following prior collaboration with Arm which resulted in accelerated virtual environments for its Arm Cortex- A720AE in 2024 and Arm Zena Comp ...

Core Viewpoint - GE HealthCare is positioned for growth in the healthcare technology sector, with a new price target set by Jefferies indicating a potential increase in stock value [1][6] Company Overview - GE HealthCare specializes in medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, competing with major players like Siemens Healthineers and Philips Healthcare [1] - The company's current stock price is $85.55, reflecting a slight increase of 1.28% [2] - Over the past year, the stock has experienced significant volatility, with a high of $94.80 and a low of $57.65, and a market capitalization of approximately $39.08 billion [2][6] Strategic Partnerships - GE HealthCare has expanded its collaboration with Imaging Biometrics Ltd, enhancing its neuroimaging capabilities with advanced tools like FTB Express maps and QSMetric [3][5] - The FTB Express tool integrates with existing workflows, providing faster access to critical data for clinicians [4] - This partnership underscores GE HealthCare's commitment to innovation and improving patient outcomes, potentially strengthening its market position [5]

Stratasys’3D printed RadioMatrix technology is now fully available in the US, offering clinicians a platform to create radio-realistic models. Made of a material called radiopaque, RadioMatrix is claimed to be the first 3D printed material that delivers control over radiopacity. This enables clinicians can produce patient-specific models with ‘fully tuneable’ visibility on X-ray-based imaging. Applicable for image-based training and surgical planning, 3D printing specialist Stratasys said the material ai ...

Group 1: AI Developments - Yann LeCun, a leading figure in AI and head of Meta's AI research lab, plans to leave Meta by year-end to start his own AI startup, with Meta intending to partner with this new venture [3][9] - The White House is working to block a proposed bill that would limit exports of crucial AI chips, indicating a strategic effort to maintain the flow of these critical technologies [5][9] - Nvidia is reporting its Q3 2025 earnings, which is highly anticipated due to its dominant position in the AI chip market [6][9] Group 2: Media and Broadcasting - Major League Baseball has secured new three-year media rights agreements with ESPN, NBC, and Netflix, covering the 2026-2028 seasons, highlighting the shift towards a mix of traditional television and streaming platforms [4][9] Group 3: Semiconductor Innovations - IBM and the University of Dayton have announced a joint research collaboration focused on developing next-generation semiconductor technologies [7][9]

ATS Corporation Conference Call Summary Company Overview - **Company**: ATS Corporation (NYSE: ATS) - **Date**: November 18, 2025 - **Speaker**: Ryan McLeod, Interim CEO Key Points Industry and Market Dynamics - **Life Sciences Sector**: ATS has six independent life science businesses, with a focus on automation and drug delivery mechanisms, particularly auto injectors, which account for approximately 10% of total revenues and 20% of life science revenues [7][15][16] - **Growth in GLP-1 Market**: The GLP-1 segment is expected to remain a significant revenue contributor over the next five years, with high growth potential due to increasing consumer demand for drug delivery devices [15][23] - **Radiopharma Growth**: Investment in radiopharmaceuticals for cancer treatment is driving growth, with a shift towards personalized medicine leading to more specific therapies [17][18] - **Wearable Devices**: ATS is involved in the development of wearable devices, expanding their market from diabetes treatment to general consumer applications [19][20] Financial Performance - **Q2 Fiscal Results**: Revenues increased by approximately 12% year-over-year, with a backlog growth of 13.5% [11][12] - **Margin Expansion**: ATS is on track for high single-digit organic growth and has seen sequential margin expansion, particularly in Q2 [12][13] - **Transportation Segment**: The transportation business has stabilized at around $50 million per quarter, with no expected growth in the next three to five years due to market saturation and technology changes [30][31] Strategic Initiatives - **Restructuring and Optimization**: ATS has undergone significant restructuring to optimize performance, particularly in the transportation segment, while exploring adjacent opportunities in industrial manufacturing and reshoring [31][33] - **Nuclear Business Growth**: The nuclear segment is expected to grow, with a focus on refurbishment, decommissioning, and new builds, particularly in the context of increasing energy demands [25][27][28] Leadership Transition - **CEO Search**: The board is actively engaged in the search for a new CEO, prioritizing candidates with strong backgrounds in continuous improvement and M&A [56][59] Other Considerations - **Working Capital Management**: ATS aims to reduce working capital investment from approximately 18% to a target of 15% of sales, with larger life science programs expected to contribute to this goal [46][48] - **Market Positioning**: ATS is focused on high-consequence markets such as life sciences and food, which are less cyclical and emphasize quality and time to market [44][45] This summary encapsulates the key insights from the ATS Corporation conference call, highlighting the company's strategic focus, market dynamics, and financial performance.

Group 1: Partnership Overview - Samsung C&T and Siemens have initiated a collaboration focusing on next-generation infrastructure projects in Saudi Arabia, Canada, and Thailand, covering sectors such as airports, hospitals, data centers, and buildings [1] - The partnership aims to leverage Siemens' Smart Infrastructure and Digital Industries portfolio, including technologies like Building X, Electrification X, and Industrial Metaverse applications, to enhance design, efficiency, and performance [1] Group 2: Company Profiles - Siemens Smart Infrastructure addresses urbanization and climate change challenges by connecting energy systems, buildings, and industries, providing a comprehensive end-to-end portfolio from power generation to consumption [2] - Siemens generated revenue of €78.9 billion and net income of €10.4 billion in fiscal 2025, employing around 318,000 people globally [2] - Samsung C&T is recognized for its engineering, procurement, and construction expertise, with landmark projects including the Burj Khalifa and the Riyadh Metro, and is focusing on eco-friendly energy solutions and AI-related infrastructures for future growth [2]

Siemens has announced plans to ‘deconsolidate’ its remaining stake in Siemens Healthineers by transferring 30% of shares to Siemens shareholders. Siemens, whose stake had stood at 67%, will hand the shares over via a direct spin-off as ‘preferable option’. Deciding to deconsolidate the Healthineers business follows a thorough assessment and strategic review of how both companies can best realise their full potential, accelerate their respective transformations, and successfully tap into new areas of grow ...

Siemens Healthineers Capital Markets Day Summary Company Overview - **Company**: Siemens Healthineers (OTCPK: SEMH.F) - **Event**: 2025 Capital Markets Day - **Date**: November 17, 2025 Key Points Industry Position and Strategy - Siemens Healthineers is recognized as a leader in the healthcare industry, particularly in imaging and precision therapies, with a strong presence in the Americas, Europe, China, and APJ regions [6][9][10] - The company operates in 70 countries and has an installed base of 700,000 systems, impacting 3 billion patients annually [6][7] - The focus is on elevating health globally, addressing non-communicable diseases (NCDs) which account for 75% of global deaths [17][18] Financial Performance - Revenue growth has averaged over 6% per year since the last capital market day, with EPS growth at 11% per year [10][58] - Siemens Healthineers reported revenues of over EUR 23 billion and EBIT close to EUR 4 billion [9] - The company has a backlog of over EUR 6 billion from value partnerships [8][12] Research and Development - Siemens Healthineers invests more than EUR 2 billion annually in R&D, with a focus on software, AI, and data science [7] - The company holds 1,300 patent families in healthcare AI, showcasing its commitment to innovation [7] Business Segments - The company operates in three synergistic business segments: Imaging, Varian (Precision Therapy), and Advanced Therapies, with Diagnostics following a separate path [9][13] - Diagnostics has improved margins by 8 percentage points since 2023 and is expected to have more entrepreneurial freedom for strategic growth [13] Future Growth and Targets - Midterm growth targets (2027-2030) include revenue growth of 5-9% and double-digit EPS growth [41][42] - The company aims for margin expansion of about 100 basis points per year in Precision Therapy and mid-single-digit growth in Diagnostics [42] - Sustainability targets include reducing carbon footprint by 90% in scope one and two by 2030 [42] Customer Challenges - Key challenges for customers include efficiency, clinical excellence, and access to care, driven by staff shortages and the need for improved healthcare systems [34][35][36] - Siemens Healthineers aims to address these challenges through value partnerships and innovative solutions [37][38] Technological Innovations - The company is focusing on personalized treatment approaches for NCDs, leveraging AI and advanced imaging technologies [22][23][24] - Innovations such as photon counting CT and AI-enabled MRI are positioned to enhance early detection and treatment planning [25][29] Capital Allocation and Financial Strategy - Siemens Healthineers has a stable dividend policy, proposing EUR 1.00 per share for the next AGM, with a commitment to maintain a progressive dividend [52] - The company targets a net debt to EBITDA ratio of 2.5 over the next two years, aiming for a strong investment-grade rating [54] Conclusion - Siemens Healthineers is well-positioned to tackle significant healthcare challenges through its innovative technologies, strong market presence, and strategic focus on growth and sustainability [39][40]

Capital Markets Day London, November 17, 2025 Unrestricted © Siemens Healthineers, 2025 1 Unrestricted © Siemens Healthineers, 2025 Capital Markets Day 2025 Safe Harbor Statement This webcast has been provided solely for use at this meeting. By attending the meeting or accessing this webcast, you agree to be bound by the following limitations. This webcast is provided in conjunction with an oral presentation and should not be taken out of context. This webcast serves for information purposes only and the in ...